TY  - JOUR
AU  - Hasoon, Jahfer
AU  - Hamilton, Calum A
AU  - Firbank, Michael
AU  - Schumacher, Julia
AU  - Colloby, Sean J
AU  - Donaghy, Paul C
AU  - Taylor, John-Paul
AU  - Thomas, Alan J
TI  - Multimodal biomarkers to predict dementia-free survival and cognitive decline in mild cognitive impairment with Lewy bodies.
JO  - Parkinsonism & related disorders
VL  - 145
SN  - 1353-8020
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DZNE-2026-00297
SP  - 108265
PY  - 2026
AB  - Predicting conversion to dementia in mild cognitive impairment with Lewy bodies (MCI-LB) remains challenging. Furthermore, there is limited research combining predictive markers in MCI-LB. We explored the utility of Lewy body and Alzheimer's disease biomarkers for the prediction of future decline in MCI-LB.Eighty-seven participants were included (35 MCI-AD, 15 possible MCI-LB, 37 probable MCI-LB). Baseline assessment involved MRI, EEG, bloods and cognitive testing. Follow up was completed yearly with review of diagnosis and repeat cognitive testing. We evaluated the relationship between baseline biomarkers and dementia-free survival time. We also investigated biomarker effects on future cognitive decline using annualised change in ACE-R. The value of combining biomarkers with baseline cognitive test score was assessed using forward selection.In probable MCI-LB, shorter dementia-free survival time was strongly associated with smaller hippocampal volume (hazard ratio = 2.36, 95
KW  - Dementia with lewy bodies (Other)
KW  - Disease progression (Other)
KW  - EEG (Other)
KW  - MRI (Other)
KW  - Mild cognitive impairment (Other)
KW  - Plasma biomarkers (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41780490
DO  - DOI:10.1016/j.parkreldis.2026.108265
UR  - https://pub.dzne.de/record/285740
ER  -